Around 50 million people have dementia. The WHO predicts this number will triple by 2050. Advancing our understanding of the fundamental basis for nervous system abnormalities and finding new and effective treatments are paramount.
At Cerba Research, top scientists and industry-leading laboratories drive the development of more advanced biomarker strategies along with custom assays and on-target protocol advice to accelerate your clinical development project.
9,813 Patients screened
1,819 Sites
41 Countries
Our Neurology Trials
34%
Alzheimer’s disease
21%
Schizophrenia
40%
FDA approvals
From Alzheimer’s biomarkers to pain studies, we’ve got you covered
We offer a variety of capabilities to help you investigate neurological disorders:
- Companion diagnostics
- Biomarkers
- Alzheimer markers: Tau, pTau, Abeta1-40, Abeta1-42
- Neurological disorders
- Psychiatric disorders
- Next generation sequencing (NGS)
- Pain studies
